Injective falls nearly 13% as technical pressures overshadow mainnet upgrade support

Injective falls nearly 13% as technical pressures overshadow mainnet upgrade support
Injective slides 12.85% today to $6.92

Injective (INJ) fell 12.85% after a sharp downward gap, with the move unfolding even as major protocol and ecosystem upgrades received strong community backing. The near-term decline is supported by technical downside pressure, as INJ trades below its 20-day and 50-day moving averages.

INJ price prediction
24H 4.08%
$7.4
48H -0.28%
$7.09
7D -5.2%
$6.74
1M -11.95%
$6.26
3M -65.12%
$2.48
6M -77.92%
$1.57
12M 22.64%
$8.72
Current price: $7.11 0.12 1.66%
Real-time Data 00:04
Daily range 6.81 Arrow from to Icon 7.4
Weekly range 6.56 Arrow from to Icon 8.25
Loading...

Highlights

  • Injective received over 99% community approval to upgrade its Veyra mainnet, targeting institutional trading and real-world asset tokenization.
  • More than $80 million in USDC stablecoin liquidity migrated on Cosmos, with updated protocols and new deposit options for dYdX users.
  • INJ/USD trades below short- and medium-term averages with a 76% probability of downside in the next five sessions, projected between $6.03 and $7.81.

Staker optimism persists despite large liquidity migration and selloff

Injective received strong community approval for the Veyra mainnet upgrade, with over 99% of stakers voting in favor as of mid-November 2026. The upgrade is aimed at expanding institutional trading and real-world asset tokenization capabilities. Injective was also at the center of a major migration of over $80 million in USDC stablecoin liquidity within the Cosmos ecosystem, with new deposit routes and updated protocols announced for dYdX users, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes that Injective's sharp 12.85% loss reflects both technical weakness and fading near-term sentiment, despite positive community responses to protocol upgrades. He sees persistent downside pressure as the asset trades under the 20-day and 50-day moving averages, while neutral readings in key momentum indicators suggest a lack of immediate recovery catalysts. The analyst is skeptical regarding the market’s ability to absorb continued selling, especially with intraday volatility running high. He highlights that bullish long-term structures are being tested as short-term supports come under threat. "Given the prevailing technical setup and broader negative sentiment, I see increased downside risk outweighing any near-term bullish cases for INJ," Kharitonov concludes.
Viktoras Karapetjanc, expert at Traders Union, sees structural strength in Injective’s fundamentals, grounded in overwhelming community support for the Veyra mainnet upgrade and expanding capabilities for real-world asset tokenization. He emphasizes that such institutional-focused developments provide a strong foundation for future inflows and market participation, even as recent volatility persists. Karapetjanc highlights the asset’s continued position above the 200-day moving average as a signal of underlying bullishness. He believes setbacks from selling pressure are temporary and see opportunity in the current price range. "With the upgrade momentum and bullish structure intact, I expect INJ to rebound toward the upper end of the projected range as market conditions normalize," Karapetjanc states.
Sholanke Dele, market strategist, underscores that sell-offs have dominated Injective even in the wake of protocol news and major USDC liquidity migration. He is notably critical of the market’s weak response to otherwise bullish institutional updates, viewing this as a sign of prevailing risk aversion. Dele warns that technical and sentiment headwinds are likely to cap any short-lived bounces. "In my view, confidence remains fragile and further losses are likely unless sentiment shifts decisively," Dele asserts.
Injective asset chart
Injective price dynamics. Source: TradingView.

Mixed indicator signals as short-term pressure meets long-term support

INJ/USD is trading below both the 20-day and 50-day moving averages at $7.72 and $7.80, respectively, but remains above the 200-day average at $5.81. This configuration points to continued downside pressure in the short and medium term, while the alignment of the 50-day and 200-day averages confirms a longer-term bullish structure. Immediate resistance is located at $7.13, today’s high, and short-term support appears at $6.66, the weekly low. Technical indicators show mixed signals: MACD, ADX, RSI, and CCI are all neutral, Stochastic RSI is in the oversold zone, Bull/Bear Power is slightly positive at 0.5, and the Awesome Oscillator remains negative, highlighting the ongoing downside bias. INJ/USD last traded at $6.92, with intraday volatility recorded at 8.69%. Selling pressure has dominated the session following significant losses after the open.

Previously it was reported that Injective was experiencing persistent short- and medium-term price pressure despite robust governance activity and institutional developments around the Veyra upgrade. The current article reinforces this outlook, with continued technical headwinds dictating a broad sideways-to-lower trading scenario and $6.66 now emerging as the critical support level to watch for potential downside acceleration.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.